We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
-$123M
Cap. Flow
-$193M
Cap. Flow %
-4.9%
Top 10 Hldgs %
32.83%
Holding
121
New
17
Increased
40
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
SGRY icon
Surgery Partners
SGRY
+$30.8M
2
LLY icon
Eli Lilly
LLY
+$24M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$20.7M
4
PHVS icon
Pharvaris
PHVS
+$20M
5
OSCR icon
Oscar Health
OSCR
+$18.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$163M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$89.3M
3
HUM icon
Humana
HUM
+$61.6M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$49.1M
5
BPMC
Blueprint Medicines
BPMC
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Consumer Staples 1.95%
3 Industrials 0.94%
4 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MREO
51
Mereo BioPharma
MREO
$43.5M
$26.9M 0.68%
8,142,109
+158,258
+2% +$536K
TVTX icon
52
Travere Therapeutics
TVTX
$5.74B
$26.4M 0.67%
3,424,818
+653,372
+24% +$5.51M
CERE
53
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$23.2M 0.59%
547,946
-2,126,299
-80% -$89.3M
IRON icon
54
Disc Medicine
IRON
$3.01B
$22.6M 0.57%
363,468
– –
COLL icon
55
Collegium Pharmaceutical
COLL
$882M
$21.8M 0.55%
562,000
– –
VKTX icon
56
Viking Therapeutics
VKTX
$4.02B
$21.4M 0.54%
+261,000
New +$11.6M
DVAX
57
DELISTED
Dynavax Technologies
DVAX
$20.8M 0.53%
1,675,474
– –
ZLAB icon
58
Zai Lab
ZLAB
$2.65B
$20.8M 0.53%
1,297,123
+160,100
+14% +$3.37M
MGNX icon
59
MacroGenics
MGNX
$259M
$19.2M 0.49%
1,305,250
+126,454
+11% +$1.91M
NVO
60
Novo Nordisk
NVO
$211B
$18.9M 0.48%
+147,500
New +$17.6M
KRYS icon
61
Krystal Biotech
KRYS
$9.81B
$18.5M 0.47%
103,969
– –
BCRX icon
62
BioCryst Pharmaceuticals
BCRX
$2.51B
$17.8M 0.45%
3,496,256
+225,875
+7% +$1.27M
GPCR icon
63
Structure Therapeutics
GPCR
$3.82B
$17.7M 0.45%
412,649
+125,973
+44% +$5.31M
PHVS icon
64
Pharvaris
PHVS
$2.43B
$17.4M 0.44%
+752,924
New +$20M
PRTA icon
65
Prothena Corp
PRTA
$468M
$15.5M 0.39%
625,048
– –
NVRO
66
DELISTED
NEVRO CORP.
NVRO
$15.4M 0.39%
1,065,000
+40,000
+4% +$661K
VERA icon
67
Vera Therapeutics
VERA
$2.27B
$14.7M 0.37%
+341,168
New +$12.2M
MRSN
68
DELISTED
Mersana Therapeutics
MRSN
$13.6M 0.35%
121,871
– –
FOLD
69
DELISTED
Amicus Therapeutics
FOLD
$13.6M 0.34%
1,152,656
+88,850
+8% +$1.14M
CRNX icon
70
Crinetics Pharmaceuticals
CRNX
$8.93B
$13.5M 0.34%
+289,400
New +$11.3M
CRL icon
71
Charles River Laboratories
CRL
$13.2B
$13.1M 0.33%
+48,500
New +$11.6M
BMRN icon
72
BioMarin Pharmaceuticals
BMRN
$13.3B
$13M 0.33%
148,832
– –
DYN icon
73
Dyne Therapeutics
DYN
$4.95B
$12.8M 0.33%
+451,824
New +$10.2M
JSPR icon
74
Jasper Therapeutics
JSPR
$26.6M
$11.9M 0.3%
+404,335
New +$7.18M
CMPX icon
75
Compass Therapeutics
CMPX
$400M
$10.9M 0.28%
5,513,788
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rock Springs Capital Management held 121 positions worth $3.94B, down 3% from $4.06B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $193M in Q1 2024, closing 7 positions and reducing 11 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $163M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Surgery Partners worth $29.4M.

  • Rock Springs Capital Management's largest Q1 2024 buy was Surgery Partners: 985,000 shares worth $29.4M.
  • Rock Springs Capital Management added most to Eli Lilly in Q1 2024, an estimated $24M increase.
  • Rock Springs Capital Management's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $89.3M.
  • Rock Springs Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $163M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $3.94B portfolio in Q1 2024.
  • Rock Springs Capital Management opened 17 new positions and closed 7 in Q1 2024.
  • Rock Springs Capital Management's portfolio value fell 3% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.